Metagenomi, Inc. (MGX) Price & Analysis

Compare

942 Followers

MGX Stock Chart & Stats

$2.16

-$0.33(-10.00%)

At close: Jan 08 4:00 PM EST

$2.16

-$0.33(-10.00%)

Day’s Range― - ―

52-Week Range$1.23 - $4.92

Previous CloseN/A

Volume382.73K

Average Volume (3M)883.52K

Market Cap

$85.95M

Enterprise Value-$107.01M

Total Cash (Recent Filing)$204.99M

Total Debt (Recent Filing)$42.99M

Price to Earnings (P/E)―

Beta0.98

Next Earnings

Nov 12, 2025

EPS Estimate

-0.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.54

Shares Outstanding37,533,134

10 Day Avg. Volume1,405,864

30 Day Avg. Volume883,524

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)0.58

Price to Sales (P/S)2.58

P/FCF Ratio-1.20

Enterprise Value/Market Cap-1.25

Enterprise Value/Revenue-3.17

Enterprise Value/Gross Profit-3.17

Enterprise Value/Ebitda1.24

Forecast

1Y Price Target

$9.00

Price Target Upside316.67% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Efficacy EvidenceMetagenomi's gene editing approach achieved durable FVIII levels over a 19-month horizon in Hemophilia A, indicating promising results.

Financial StabilityManagement expects the cash and cash equivalents of ~$205M to provide an operational runway into 2027, indicating financial stability.

Partnership DevelopmentMetagenomi continues to guide to the selection of at least one development candidate from its cardiometabolic partnership with Ionis in 2025, showing active collaboration efforts.

Bears Say

Clinical Advancement RisksRisks include delays in advancing pipeline candidates into and through clinical assessment, affecting progress.

Financial ChallengesMGX reported a Q2 net loss of $19.9MM, pointing to financial challenges.

Long-term Dilution RiskPossible long-term dilution risk is mentioned as a concern for investors.

Metagenomi, Inc. News

Video: This stock is dragging down the in vivo gene editing therapy space

The Fly has brought its to-the-moment stock market reporting to YouTube! Listen and subscribe. Published first on TheFly...

14d ago

MGX

BEAM

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $30...

15d ago

MGX

CRSP

Amazon’s (AMZN) Alexa Chips are More Powerful than Nvidia in Fighting Disease, Says Biotech

Amazon ($AMZN) has come out on top of rivals such as Nvidia ($NVDA) when it comes to utilizing...

19d ago

MGX

AMZN

MGX Upcoming Earnings Report: What to Expect?

Metagenomi, Inc. (MGX) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street analysts...

19h ago

MGX

Metagenomi Regains Control After Affini-T Agreement Termination

The latest update is out from Metagenomi, Inc. ( ($MGX) ). On September 29, 2025, Metagenomi, Inc. entered...

1M ago

MGX

AbCellera appoints Sarah Noonberg as Chief Medical Officer

AbCellera (ABCL) announced the appointment of Sarah Noonberg as Chief Medical Officer. Noonberg brings over two decades of...

2M ago

MGX

ABCL

Promising Prospects for Metagenomi, Inc.: Strategic Partnerships and Strong Financial Position Highlight Upside Potential

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Metagenomi, Inc.. The associated price target...

3M ago

MGX

Metagenomi price target lowered to $11 from $12 at Chardan

Chardan lowered the firm’s price target on Metagenomi (MGX) to $11 from $12. The firm updated its model...

3M ago

MGX

Metagenomi, Inc. Reports Q2 2025 Financial Results

Metagenomi, Inc. ( ($MGX) ) has released its Q2 earnings. Here is a breakdown of the information Metagenomi,...

3M ago

MGX

Metagenomi reports Q2 EPS (54c), consensus (61c)

Reports Q2 revenue $8.51M, consensus $7.72M. The company ended the quarter with $205.M in cash, cash equivalents, and...

3M ago

MGX

Metagenomi Reports Strong Q2 2025 Financial Results

Metagenomi, Inc. ( ($MGX) ) has shared an announcement. Metagenomi, Inc. reported its second quarter 2025 financial results...

3M ago

MGX

MGX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Metagenomi, Inc. (MGX) is scheduled to report 2nd quarter earnings on 08/13/2025. Regarding Q2 estimates, Wall Street analysts...

3M ago

MGX

Metagenomi, Inc. Holds Annual Stockholders Meeting

Metagenomi, Inc. ( ($MGX) ) just unveiled an announcement. On June 10, 2025, Metagenomi, Inc. held its annual...

5M ago

MGX

Metagenomi Reports Promising Hemophilia A Study Results

Metagenomi, Inc. ( ($MGX) ) has released its Q1 earnings. Here is a breakdown of the information Metagenomi,...

6M ago

MGX

MGX FAQ

What was Metagenomi, Inc.’s price range in the past 12 months?

Metagenomi, Inc. lowest stock price was $1.23 and its highest was $4.92 in the past 12 months.

What is Metagenomi, Inc.’s market cap?

Metagenomi, Inc.’s market cap is $85.95M.

When is Metagenomi, Inc.’s upcoming earnings report date?

Metagenomi, Inc.’s upcoming earnings report date is Nov 12, 2025 which is tomorrow.

How were Metagenomi, Inc.’s earnings last quarter?

Metagenomi, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.619 by $0.079.

Is Metagenomi, Inc. overvalued?

According to Wall Street analysts Metagenomi, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Metagenomi, Inc. pay dividends?

Metagenomi, Inc. does not currently pay dividends.

What is Metagenomi, Inc.’s EPS estimate?

Metagenomi, Inc.’s EPS estimate is -0.58.

How many shares outstanding does Metagenomi, Inc. have?

Metagenomi, Inc. has 37,533,134 shares outstanding.

What happened to Metagenomi, Inc.’s price movement after its last earnings report?

Metagenomi, Inc. reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.619. Following the earnings report the stock price went up 3.191%.

Which hedge fund is a major shareholder of Metagenomi, Inc.?

Currently, no hedge funds are holding shares in MGX

Metagenomi, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-37.45%

Trailing 12-Months

Asset Growth

-29.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Metagenomi, Inc.

Metagenomi, Inc. (MGX) is a biotechnology company focused on developing innovative gene editing technologies and therapeutic solutions for genetic disorders. Operating primarily in the biotechnology and life sciences sectors, Metagenomi leverages its proprietary gene-editing platform to create precise, efficient, and safe gene therapies. The company's core products include gene-editing tools that enable targeted modifications to the genome, with applications across various therapeutic areas, including rare diseases, cancer, and infectious diseases.

Metagenomi, Inc. (MGX) Earnings & Revenues

Historic Earnings Reports

MGX Stock 12 Month Forecast

Average Price Target

$9.00

▲(316.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","9":"$9","12":"$12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3,6,9,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.39,3.0523076923076924,3.7146153846153847,4.376923076923077,5.03923076923077,5.701538461538462,6.363846153846154,7.026153846153846,7.688461538461539,8.350769230769231,9.013076923076923,9.675384615384615,10.337692307692308,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.39,2.8984615384615386,3.4069230769230767,3.9153846153846152,4.423846153846154,4.932307692307692,5.440769230769231,5.949230769230769,6.457692307692307,6.966153846153846,7.474615384615385,7.983076923076922,8.491538461538461,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.39,2.7446153846153845,3.0992307692307692,3.453846153846154,3.8084615384615383,4.163076923076923,4.5176923076923075,4.872307692307691,5.226923076923077,5.581538461538461,5.936153846153846,6.2907692307692304,6.645384615384614,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.07,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.11,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >